🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Lite Strategy, Inc. LITS PHARMA

Healthcare · Biotechnology · United States
https://www.litestrategy.com
Company Profile ↓
$1.10
-78.60% 1Y
Mkt Cap$37.43M
P/E-0.53
P/B0.70
52W High$5.28
52W Low$0.74
Book Value$1.62
EPS (TTM)$-2.08

Company Overview

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%, earnings -189.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Compounded Profit Growth

5 Years:-
1 Year:-189.69%

Stock Price Performance

1 Year:-78.60%
6 Months:-8.33%
3 Months:+46.67%
1 Month:+20.88%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 8% of range
$0.74 $5.28
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)63.62 · Neutral
Price Performance
1M+20.88%
3M+46.67%
6M-8.33%
1Y-78.60%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 79.2% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.53
Industry PE
24.83
Forward P/E
-
PEG Ratio
2.22
Book Value
$1.62
Price to Book
0.70
P/S
-
EV/EBITDA
-1.79
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-189.69%

Profitability & Returns

ROCE
-103.09%
ROE
-
ROA
-27.69%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.66
EPS (TTM)
$-2.08

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
7.92
Current Ratio
11.53
Debt
$0
Total Assets
$57.79M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.16%
Chg in Prom Hold
-10.80%
FII / Inst Holding
17.31%
Chg in FII Hold
-0.54%

Financial Snapshot

Enterprise Value
$37.43M
Total Revenue (TTM)
$0
EBITDA
$-17.13M
Free Cash Flow
$-13.42M
Operating Cash Flow
$-10.42M
Shares Outstanding
34.03M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LITS Lite Strategy, Inc. PHARMA 1.10 -0.53 $37.43M 0.00% -103.09% - - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Sep 2021Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue ------1.10M17.20M4.50M449.00K283.00K358.00K433.00K548.00K488.00K2.05M1.25M1.13M1.16M1.01M1.24M25.50M3.83M9.17M8.11M7.76M11.83M9.69M8.73M32.73M5.89M65.30M00000---
Operating Income -8.96M--4.65M-5.13M-5.41M--4.32M11.82M-670.00K--8.89M-6.17M-6.05M--10.03M-11.85M-12.62M--12.62M-12.11M-12.44M--15.59M-19.20M-16.39M-20.11M-17.62M-21.56M-18.22M8.93M-16.39M55.28M-11.93M-9.83M-8.35M-3.45M-2.77M-3.74M-29.87M-21.61M
Net Income -8.93M-5.66M-4.62M-5.10M-5.37M-5.77M-4.27M11.88M-602.00K-4.34M-8.79M-6.08M-5.95M-19.25M-14.54M12.03M-17.35M3.05M-2.99M-20.22M-4.33M-18.48M712.00K-8.03M-25.62M-17.51M-12.16M-8.72M-16.62M10.25M-15.44M56.37M-11.06M-9.13M-8.01M-2.68M-2.57M-3.64M-30.80M-23.69M
Diluted EPS ---0.13-0.15-0.16-0.17-0.120.32-0.02-0.12-0.24-0.16-0.16-0.36-0.21-0.15-0.24-0.15-0.04-0.26-0.04-0.17-0.13-0.16-0.23-0.18-0.14-1.31-2.491.54-2.328.46-1.66-1.37-1.20-0.40-0.39-0.12-0.82-0.66
R&D Expense 6.78M-2.82M3.18M3.42M-1.65M1.64M1.88M-6.06M3.44M3.07M-6.13M9.07M9.07M-8.96M8.28M8.96M-13.00M22.22M17.88M19.95M21.53M22.32M19.46M15.31M15.10M3.48M3.91M5.22M3.16M308.00K369.00K10.00K46.00K30.00K

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2002Jun 2003Jun 2004Jun 2005Jun 2006Jun 2007Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Revenue ---------------23.25M1.62M4.92M27.76M34.80M40.70M48.82M65.30M0
Operating Income ----------6.45M-8.39M-11.22M-27.23M-32.77M-21.00M2.38M-28.59M-46.24M-25.70M-60.42M-75.48M-36.76M14.54M-17.45M
Net Income -123.00K-3.03M-8.54M-6.42M-7.39M-13.82M-12.41M-11.18M-7.90M-6.78M-7.52M-11.19M-27.15M-32.69M-20.86M2.67M-40.07M-16.82M-47.17M-41.31M-54.45M-32.00M17.78M-15.95M
Diluted EPS --------------1.16-0.610.07-0.97-0.75-0.52-0.60-9.99-4.782.67-2.39
R&D Expense ---------2.12M4.92M6.08M19.33M23.82M13.40M7.24M17.04M32.30M34.06M69.40M85.64M52.45M16.56M3.92M

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2002Jun 2003Jun 2004Jun 2005Jun 2006Jun 2007Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Assets ---------4.17M6.37M36.55M49.81M64.75M47.16M55.70M104.66M82.66M209.73M174.10M177.84M120.81M41.38M18.29M
Total Equity 8.90M5.93M22.94M16.52M9.13M13.78M16.54M15.21M7.38M1.79M4.60M34.87M45.19M59.79M41.65M50.84M50.46M47.93M77.06M49.47M52.41M24.62M33.02M16.93M
Cash & Equivalents --------9.03M3.86M6.20M35.57M13.78M18.72M10.84M8.46M13.31M9.59M12.33M8.54M15.74M16.91M3.71M18.01M
Total Liabilities ---------2.37M1.77M----4.87M54.20M34.73M131.51M124.63M125.43M96.19M8.36M1.35M
Current Liabilities ---------2.37M1.77M1.68M4.62M4.96M5.51M4.87M7.88M14.30M23.30M20.21M24.44M20.34M8.36M1.35M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Operating Cash Flow -6.50M-7.08M-10.04M---17.86M3.49M-21.04M-29.42M34.26M-31.96M-48.75M-52.48M-50.47M-20.84M
Investing Cash Flow -48.00K--38.00K--9.97M-10.08M-44.33M24.32M-106.29M24.71M6.89M53.69M49.14M35.15M
Financing Cash Flow 1.38M9.43M39.45M---4.21M70.21M1.39M74.78M3.47M49.05M-40.00K-11.87M0
Capital Expenditure -48.00K--38.00K-50.00K-15.00K-4.00K-51.00K--217.00K-894.00K-708.00K-479.00K-35.00K-7.00K-0
Free Cash Flow -6.55M--10.08M---17.86M3.44M--29.64M33.36M-32.67M-49.23M-52.52M-50.48M-20.84M
Dividends Paid ------------011.66M0

Ratios (Annual)

Figures in %.

Metric Jun 2002Jun 2003Jun 2004Jun 2005Jun 2006Jun 2007Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Gross Margin % ------------------------
Operating Margin % ---------------10.3%-1,762.4%-940.9%-92.6%-173.7%-185.5%-75.3%22.3%-
Net Margin % ---------------11.5%-2,470.3%-342.2%-170.0%-118.7%-133.8%-65.6%27.2%-
ROE % -1.4%-51.1%-37.2%-38.9%-80.9%-100.3%-75.1%-73.5%-107.0%-378.0%-163.6%-32.1%-60.1%-54.7%-50.1%5.3%-79.4%-35.1%-61.2%-83.5%-103.9%-130.0%53.8%-94.2%
ROCE % ----------359.6%-182.5%-32.2%-60.2%-54.8%-50.4%4.7%-29.5%-67.6%-13.8%-39.3%-49.2%-36.6%44.0%-103.1%

Shareholding Pattern

Insiders
1.16%
Institutions
17.31%
Public Float
17.51%

Top Institutional Holders

#Holder% HeldSharesValue
1 Renaissance Technologies, LLC 3.67% 1.25M $1.41M
2 Vanguard Capital Management LLC 3.00% 1.02M $1.15M
3 RLH Capital LLC 2.37% 806.43K $911.27K
4 Two Sigma Investments, LP 1.64% 557.01K $629.42K
5 Geode Capital Management, LLC 1.07% 365.02K $412.47K
6 Citadel Advisors Llc 1.05% 357.53K $404.01K
7 Blackrock Inc. 0.81% 275.83K $311.69K
8 Marshall Wace LLP 0.68% 232.98K $263.27K
9 Vanguard Fiduciary Trust Co 0.57% 195.39K $220.79K
10 Jane Street Group, LLC 0.57% 192.63K $217.67K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LITS

Google News Sat, 05 Sep 2026

Is Lite Strategy (NASDAQ:LITS) In A Good Position To Deliver On Growth Plans? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxNUjRPR3g2dm9Jd2hzWVVwMElmR3gzX3JMWUZwODl6OVFYQ29BMFpYSU9sTlMyRjkzVFdTOFBpb0JZa3BQOGNVUUs5NE9zOG1JdEx6ZnJyaVo0MjVKR0JuQjYxTHotUFYzNTRPTElacTJhUGdlOEtNZVpoQVhISE13aHc2OERqanV6VzdnZU…

Google News Sat, 25 Apr 2026

Is Lite Strategy (NASDAQ:LITS) In A Good Position To Invest In Growth? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNckNRZ1ZUR2JQTHJUX0hNOHRGTkxlVXFLNnZ4YVlBZUNseWdLS1d4c1FkQ3gwMEUzYkluczZiRURQUWhpbVRjcVRhUnl4R0hvVDRxVWVVSjBsclNaNGF5TmwySlRjWFRSQmhEaUU0amhsUUtxNTlFeHZoNFc4MERvMXlWY0JQT3NSeEN4UC…

Google News Fri, 04 Sep 2026

Lite Strategy, Inc. (NASDAQ: LITS) Share Price, LITS Stock News, LITS Share Price & Updates - kalkine.com.au

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5KMGoxTm83cndpMlJaSkJpdEx4cE1lREJ5czBINHdReEI2QnZzRWF0Rk1mNTRpN0U2SGlpYnhRUkNjU2JaaHQxQ3kxVW5mZl9OUTJCd2pR?oc=5" target="_blank">Lite Strategy, Inc. (NASDAQ: LITS) Share Price, LIT…

Google News hu, 03 Sep 2026

Lite Strategy Inc. (LITS) Holds Ground at $1.04 as Range-Bound Trading Persists - Gap Up Stocks - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNMFRERkhGYV9tUHlkay1DOVg0dmhQWndxWW8tMVlLNlU0c3lCRjQ0WWZvUDdRRXYtZlB4T3RRcGRObC1BMnJjZVBsVFBJM1ZjSVZ5TXZRU25SNlF1U0VQZFVGQUtfRTRsRVN1T2JTNkx6M1RBdEo3OGZMbXhxM0x5WW1uNFFfcnZHbHdOM2…

Google News Fri, 16 Jan 2026

Lite Strategy, Inc. (LITS) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFBMMHliaVlnTlRfMnVPaTMwZF9iQzgyTUhsWHhtanVGYXFFNElRclg0RXlVbzI1NHgtM0tNQjQ2cklXOXFwbXQ3a0tyb09abnI2Zmc?oc=5" target="_blank">Lite Strategy, Inc. (LITS) Profile, Company FAQs & Facts…

Google News Fri, 19 Jun 2026

Lite Strategy, Inc. to Join Litecoin Foundation Summit Panel on Litecoin’s Institutional Opportunity - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNcEUxUmJTZTU3YzVfS2tmbUpPbzVwd253M2hiWmp3UGJlQ1dTR1o0a1FlTkVEV1p3a3pQSWltM2diXy1mWnRKc25wc0U0Nmp1cDJqRUJhbTh6N0VfTnNPWnNZazJkbnNqSVlvLUpxMFBMNUI0Wm95NlBxMmFEamhpOXpVajdzZEE3VGVkaV…

LITS — Frequently Asked Questions

What is the current share price of Lite Strategy, Inc. (LITS)?

As of 2026-09-19 21:16 PDT, Lite Strategy, Inc. (LITS) trades at $1.10 on NasdaqCM. Its 52-week range is $0.74 to $5.28.

What is the market capitalisation of LITS?

Lite Strategy, Inc. (LITS) has a market capitalisation of $37.43M on NasdaqCM.

What is the P/E ratio of LITS?

LITS trades at a trailing price-to-earnings (P/E) ratio of -0.53. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.70.

Is LITS a good stock to buy?

This page provides a data-driven analysis of Lite Strategy, Inc. (LITS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space